Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Otopeni – page 36

679 clinical trials in Otopeni, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Otopeni at a glance
679
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

679 trials in Otopeni

Open in trial search

Asthma

Not recruiting

Comparison of CHF5993 (glycopyrronium bromide, formoterol fumarate dihydrate, and beclometasone dipropionate) and a drug combination for patients with mild to moderate asthma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Chiesi Farmaceutici S.p.A.

A Study to Evaluate LY3537021 and a Drug Combination for Treating Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:Aprepitant
  • Sponsor:Eli Lilly & Co.

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran
  • Sponsor:Merck Healthcare KGaA

HIV infection

Not recruiting

Safety, Tolerability and Antiretroviral Activity of a Single Oral Dose of MK-8527 in ART‑Naïve Adults with HIV‑1

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years
  • Substances:MK-8527
  • Sponsor:Merck Sharp & Dohme LLC

Phase 3 Study of Subcutaneous Pembrolizumab with Hyaluronidase vs. Intravenous Pembrolizumab in Metastatic NSCLC with PD-L1 TPS ≥50%

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Study comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Breast cancer+3

Not recruiting

Study of romiplostim for treating low platelet counts caused by chemotherapy in adults with non-small cell lung cancer, ovarian cancer, or breast cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Otopeni

What the registry says about research in the country

01 Lung Cancer Research

Investigating innovative treatments for non-squamous non-small cell lung cancer (NSCLC), with a focus on patients exhibiting specific genetic markers like c-Met overexpression. Studies are evaluating the effectiveness of targeted therapies compared to standard treatments.

  • EGFR wildtype NSCLC
  • Treatment resistance patterns
  • Targeted therapy approaches

Research aims to improve survival rates and treatment outcomes for lung cancer patients.

02 Urological Oncology

Comprehensive studies focusing on renal cell carcinoma and high-risk prostate cancer. Clinical trials are exploring combination therapies and novel treatment approaches including hormone therapy with radiation treatment.

  • Advanced kidney cancer treatments
  • Prostate cancer management
  • Combination therapy efficacy

Research centers on improving disease-free survival and treatment outcomes.

03 Skin Cancer Studies

Groundbreaking research in advanced melanoma treatment, investigating the potential of combination immunotherapy approaches. Studies are comparing various therapeutic combinations to establish optimal treatment protocols.

  • Immunotherapy combinations
  • Advanced melanoma management
  • Treatment effectiveness markers

Focus on developing more effective first-line treatments for unresectable melanoma.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.